Changes in the metabolism of axillary lymph node cells as a predictor of regional metastasis in breast cancer

doi:10.5493/wjem.125128

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315X

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Exp Med. Sep 20, 2026; 16(3): 125128
Published online Sep 20, 2026. doi: 10.5493/wjem.125128

Table 7 Values of the delayed luminescence of erythrosine in accordance with the clinical and pathological characteristics of breast cancer

	Indicator 1		Indicator 2		Indicator 3		Indicator 4		Indicator 5		Indicator 6
	mean ± SD	P value	mean ± SD	P value	mean ± SD	P value	mean ± SD	P value	mean ± SD	P value	mean ± SD	P value
Age
≥ 60 years	0.86 ± 0.12	0.5941	1.21 ± 0.12	0.2750	9.89 ± 4.56	0.3414	0.81 ± 0.18	0.4134	0.16 ± 0.10	0.0877	16.68 ± 4.71	0.8697
> 60 years	0.92 ± 0.14	0.5941	1.23 ± 0.34	0.2750	10.29 ± 4.88	0.3414	0.87 ± 0.15	0.4134	0.11 ± 0.12	0.0877	18.13 ± 11.22	0.8697
T stage
T1	0.90 ± 0.15	0.3033	1.24 ± 0.33	0.8437	9.75 ± 4.95	0.6492	0.85 ± 0.17	0.5262	0.12 ± 0.12	0.0917	17.32 ± 5.37	0.1069
T2	0.88 ± 0.15	0.3033	1.20 ± 0.10	0.8437	10.24 ± 4.66	0.6492	0.83 ± 0.17	0.5262	0.15 ± 0.12	0.0917	18.71 ± 14.02	0.1069
N stage
N0-1	0.91 ± 0.14	0.1723	1.22 ± 0.29	0.0050^a	10.50 ± 4.72	0.0024^a	0.86 ± 0.16	0.0609	0.11 ± 0.10	0.0011^a	18.44 ± 9.73	0.0262
N2-3	0.84 ± 0.17	0.1723	1.27 ± 0.13	0.0050^a	6.88 ± 4.39	0.0024^a	0.76 ± 0.18	0.0609	0.21 ± 0.15	0.0011^a	14.38 ± 4.75	0.0262
Tumor grade (G)
G1-G2	0.89 ± 0.14	0.0644	1.28 ± 0.36	0.5353	9.68 ± 5.03	0.0854	0.85 ± 0.16	0.0112^a	0.12 ± 0.13	0.0233^a	17.11 ± 4.62	0.6598
G3	0.87 ± 0.17	0.0644	1.19 ± 0.10	0.5353	9.20 ± 4.55	0.0854	0.79 ± 0.17	0.0112^a	0.16 ± 0.10	0.0233^a	19.71 ± 13.87	0.6598
Lymphovascular invasion
No	0.92 ± 0.13	0.0485	1.22 ± 0.30	0.0116^a	10.64 ± 4.67	0.0011^a	0.86 ± 0.16	0.0148^a	0.11 ± 0.11	0.0002^a	16.85 ± 4.71	0.8889
Present	0.83 ± 0.17	0.0485	1.25 ± 0.12	0.0116^a	7.41 ± 4.64	0.0011^a	0.77 ± 0.18	0.0148^a	0.20 ± 0.13	0.0002^a	20.99 ± 17.17	0.8889
Perineural invasion
No	0.89 ± 0.15	0.2516	1.24 ± 0.30	0.8213	10.23 ± 4.82	0.1518	0.84 ± 0.18	0.5325	0.13 ± 0.11	0.5280	17.92 ± 9.57	0.9382
Present	0.94 ± 0.13	0.2516	1.20 ± 0.10	0.8213	8.28 ± 4.72	0.1518	0.85 ± 0.11	0.5325	0.11 ± 0.17	0.5280	17.12 ± 7.30	0.9382
Intraductal component
No	0.94 ± 0.13	0.1241	1.19 ± 0.12	0.8235	9.69 ± 4.91	0.8333	0.84 ± 0.16	0.6577	0.11 ± 0.16	0.5651	15.95 ± 6.25	0.1780
Present	0.89 ± 0.30	0.1241	1.22 ± 0.30	0.8235	9.97 ± 4.84	0.8333	0.84 ± 0.17	0.6577	0.13 ± 0.11	0.5651	18.23 ± 9.77	0.1780
Breast cancer subtype
Luminal A	0.89 ± 0.16	0.5386	1.20 ± 0.12	0.2972	9.29 ± 5.09	0.9772	0.84 ± 0.17	0.5558	0.13 ± 0.12	0.13 ± 0.12	18.19 ± 11.95
Luminal B HER2-	0.89 ± 0.11		1.30 ± 0.47		10.50 ± 4.72		0.87 ± 0.16		0.11 ± 0.12		17.18 ± 3.11	0.2159
Luminal B HER2+	0.86 ± 0.11		1.25 ± 0.03		10.00 ± 5.77		0.85 ± 0.17		0.17 ± 0.01		24.75 ± 8.62
HER2+	0.95 ± 0.14		1.12 ± 0.11		10.63 ± 4.71		0.89 ± 0.11		0.14 ± 0.13		15.16 ± 5.26
TNBC	0.90 ± 0.20		1.23 ± 0.08		11.35 ± 3.28		0.74 ± 0.21		0.20 ± 0.07		16.64 ± 3.50
Estrogen receptor status
Negative	0.93 ± 0.18	0.9020	1.18 ± 0.10	0.6652	11.03 ± 3.87	0.2022	0.81 ± 0.18	0.2178	0.17 ± 0.10	0.0554	15.98 ± 4.29	0.5662
Positive	0.89 ± 0.14	0.9020	1.24 ± 0.29	0.6652	9.73 ± 4.97	0.2022	0.85 ± 0.16	0.2178	0.12 ± 0.12	0.0554	18.09 ± 9.79	0.5662
Progesterone receptor status
Negative	0.92 ± 0.17	0.6149	1.20 ± 0.10	0.8460	11.04 ± 4.71	0.0848	0.85 ± 0.18	0.4543	0.11 ± 0.13	0.4510	18.06 ± 5.33	0.2230
Positive	0.89 ± 0.13	0.6149	1.24 ± 0.32	0.8460	9.38 ± 4.83	0.0848	0.84 ± 0.16	0.4543	0.14 ± 0.11	0.4510	17.66 ± 10.60	0.2230
Human epidermal growth factor receptor 2 status
Negative	0.89 ± 0.15	0.8055	1.24 ± 0.29	0.4746	9.86 ± 4.86	0.5958	0.84 ± 0.17	0.7991	0.13 ± 0.12	0.4746	17.73 ± 9.39	0.6171
Positive	0.93 ± 0.14	0.8055	1.17 ± 0.11	0.4746	10.42 ± 4.83	0.5958	0.88 ± 0.12	0.7991	0.15 ± 0.10	0.4746	18.36 ± 7.76	0.6171
Ki67 index
< 40%	0.90 ± 0.15	0.7704	1.19 ± 1.12	0.0561	9.31 ± 4.99	0.0315	0.84 ± 0.16	0.2328	0.12 ± 0.12	0.02349^a	17.88 ± 10.88	0.6379
≥ 40%	0.90 ± 0.14	0.7704	1.31 ± 0.43	0.0561	11.11 ± 4.32	0.0315	0.85 ± 0.18	0.2328	0.15 ± 0.13	0.02349^a	17.61 ± 4.56	0.6379

^aP value < 0.0250 is considered significant.

HER2: Human epidermal growth factor receptor 2; TNBC: Triple-negative breast cancer.

Full Size Table

Citation: Senchukova MA, Ishemgulov AT, Letuta SN, Saidler NV, Tagabilev DG. Changes in the metabolism of axillary lymph node cells as a predictor of regional metastasis in breast cancer. World J Exp Med 2026; 16(3): 125128
URL: https://www.wjgnet.com/2220-315X/full/v16/i3/125128.htm
DOI: https://dx.doi.org/10.5493/wjem.125128

Senchukova MA, Ishemgulov AT, Letuta SN, Saidler NV, Tagabilev DG. Changes in the metabolism of axillary lymph node cells as a predictor of regional metastasis in breast cancer. World J Exp Med 2026; 16(3): 125128 [DOI: 10.5493/wjem.125128]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.